Lululab Inc. (CEO Yongjun Choi), an AI skin analysis solution company, has signed an exclusive domestic distribution agreement with medical and bio company LNC Bio for its AI 3D skin diagnosis solution, 'LuskinX'. Through this agreement, Lululab plans to expand its solution into the hospital and clinic markets in earnest by leveraging LNC Bio's domestic hospital and clinic network and market influence.
LuskinX is an AI 3D skin diagnosis solution that analyzes key skin indicators such as redness, pigmentation, pores, wrinkles, and acne through general light, polarized light, and UV composite photography. It utilizes a deep learning algorithm trained on over 5 million skin data from approximately 60 countries, providing an integrated score and quantified indicators such as depth, size, and number of each item. This solution was developed based on lululab's seven AI analysis technologies and approximately 35 technical papers.
Based on diagnostic results, RuskinX provides customized treatment recommendations, predictive simulations, and pre- and post-treatment comparison reports, empowering medical professionals to develop data-driven consultation and treatment strategies. With the recent growth of the Skin Booster market, demand for data-driven precision diagnosis is also on the rise.
Through this collaboration, Lululab will provide a data-driven consultation environment linked to LNC Bio's flagship product, "Lituo," and other key treatment solutions. This will allow medical professionals to develop personalized treatment strategies, while patients can increase their trust and satisfaction with their treatment based on visual and quantitative evidence.
"AI skin diagnosis is becoming a core infrastructure supporting medical decision-making," said Lululab CEO Yongjun Choi. "This collaboration is significant in that it presents an integrated AI platform model that connects diagnosis, recommendation, treatment, and result comparison. Together with LNC Bio, we will expand the data-driven precision treatment environment in the domestic medical market and strengthen our global K-beauty tech competitiveness."
- See more related articles
You must be logged in to post a comment.